3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
18
Sarcoma
15
Burkitt Lymphoma
9
Breast Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Lymphoma, T-Cell, Peripheral
7
Lymphoma, Follicular
7
Lymphoma, B-Cell
7
Ovarian Neoplasms
6
Lymphoma
6
Hodgkin Disease
6
Endometrial Neoplasms
5
Osteosarcoma
4
Neuroblastoma
4
Lymphoma, Non-Hodgkin
4
Liposarcoma
4
Recurrence
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Peritoneal Neoplasms
3
Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Leiomyosarcoma
3
Histiocytoma, Malignant Fibrous
3
Hemangiosarcoma
3
Colorectal Neoplasms
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Sarcoma, Synovial
2
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
ivosidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
Doxorubicin
×
Clear all
NCT05959720
2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
180 enrolled